Valuation: Polaris Group

Market Cap 11.31B 355M 310M 284M 265M 503M 33.75B 511M 3.42B 1.33B 16.55B 1.33B 1.3B 57.04B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 11.82B 371M 324M 297M 277M 526M 35.29B 535M 3.58B 1.39B 17.31B 1.39B 1.36B 59.65B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
34.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.87%
1 week-2.95%
Current month-2.95%
1 month+0.38%
3 months-35.22%
6 months-57.72%
Current year-57.72%
1 week 12.5
Extreme 12.5
14.35
1 month 12.5
Extreme 12.5
14.35
Current year 12.5
Extreme 12.5
35.95
1 year 12.5
Extreme 12.5
44.55
3 years 12.5
Extreme 12.5
91.1
5 years 12.5
Extreme 12.5
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.87%-2.95%-66.96%-83.88% 362M
+0.36%+6.85%+0.11%+5.85% 48.62B
+0.92%+6.21%+408.85%+605.33% 39.86B
+1.89%+11.06%+25.75%-6.35% 33.91B
+2.38%+8.10%+21.83%+64.58% 32.32B
+1.20%+2.26%+15.60%+32.43% 24.73B
+2.51%+4.94% - - 16.63B
+2.58%+7.24%+71.03%+133.27% 15.52B
+0.99%+3.16%+13.75%+18.88% 13.63B
-1.14%+7.52%+14.75%-28.79% 13.41B
Average +0.76%+7.43%+56.08%+82.37% 23.9B
Weighted average by Cap. +0.95%+7.72%+88.73%+130.41%

Financials

2024 2025
Net sales 107M 3.35M 2.93M 2.69M 2.51M 4.76M 319M 4.84M 32.41M 12.56M 157M 12.6M 12.32M 540M 40.6M 1.27M 1.11M 1.02M 953K 1.81M 121M 1.84M 12.3M 4.77M 59.44M 4.78M 4.68M 205M
Net income -2.5B -78.46M -68.56M -62.96M -58.71M -111M -7.47B -113M -758M -294M -3.66B -295M -288M -12.62B -3.93B -123M -108M -98.79M -92.13M -175M -11.72B -178M -1.19B -461M -5.75B -462M -452M -19.81B
Net Debt 9.19M 288K 252K 231K 216K 409K 27.44M 416K 2.78M 1.08M 13.46M 1.08M 1.06M 46.37M 517M 16.21M 14.16M 13M 12.13M 22.99M 1.54B 23.38M 157M 60.68M 757M 60.85M 59.53M 2.61B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
02/07/26 TWD 13.15 -1.87% 1,160,519
01/07/26 TWD 13.40 -1.11% 1,872,902
30/06/26 TWD 13.55 +2.26% 1,274,774
29/06/26 TWD 13.25 +6.00% 1,513,600
26/06/26 TWD 12.50 -4.21% 2,171,938
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock